"May be seen as a unilateral mass continuously filling the pulmonary artery with inhomogenous, heterogenous enhancement. Features of vascular distension, extravascular invasion into adjacent structures may be present."
"T1 C+ (Gd): shows enhancement or areas of enhancement 13"
Expected headings
"FDG-PET"
"It is an extremely malignant tumour with median survival times of all patients according to one publication of around 1.5 months with possible prolonged to 10 months with surgery such as pneumonectomy +/- excision of the tumour from the vascular bed. Early detection and surgical resection improves patient survival, the benefits of adjuvant therapy are not well understood. Systemic metastases have been reported in around 20% of cases at diagnosis and sites include the liver, pancreas, mesentery, brain, adrenals, kidneys, thyroid and the skin 9. Frequency of metastatic disease is not thought to be related to original tumour size,"
"It is an extremely malignant tumour with median survival times of all patients according to one publication of around 1.5 months with possible prolonged to 10 months with surgery such as pneumonectomy +/- excision of the tumour from the vascular bed. Early detection and surgical resection improves patient survival, the benefits of adjuvant therapy are not well understood. Systemic metastases have been reported in around 20% of cases at diagnosis and sites include the liver, pancreas, mesentery, brain, adrenals, kidneys, thyroid and the skin 9. Frequency of metastatic disease is not thought to be related to original tumour size,"